Description

Amoxicillin (Abiklav) Pharmacodynamics

Amoxicillin is a semi-synthetic antibiotic with a broad spectrum of antibacterial activity against many gram-positive and gram-negative microorganisms. Amoxicillin is sensitive to β-lactamase and breaks down under its influence, so the spectrum of activity of amoxicillin does not include microorganisms that synthesize this enzyme.

Clavulanic acid has a β-lactam structure similar to penicillins and inactivates β-lactamase enzymes that produce microorganisms resistant to penicillins and cephalosporins. In particular, clavulanic acid has pronounced activity against clinically important plasmid β-lactamases, which are often responsible for the emergence of cross-resistance to antibiotics. The presence of clavulanic acid in the composition of the drug protects amoxicillin from degradation due to the action of β-lactamases and expands the spectrum of antibacterial action of amoxicillin.

Pharmacokinetics

The pharmacokinetic parameters of the two components of the drug are closely related. The peak concentration in blood serum of both components is reached approximately 1 hour after oral administration of the drug. The optimal level of absorption is achieved if the drug is taken at the beginning of a meal.

Doubling the dose of Amoxicillin (Abiklav) increases the level of the drug in the blood serum by approximately two times.

Both components of the drug, clavulanate and amoxicillin, have a low level of binding to blood serum proteins, approximately 70% of them remain in the blood serum in an unbound state.

Indications

Film-coated Amoxicillin (Abiklav) Tablets 500 mg/125 mg.

Treatment of bacterial infections caused by microorganisms sensitive to the drug, such as:

• acute bacterial sinusitis;
• acute otitis media;
• confirmed exacerbation of chronic bronchitis;
• nosocomial pneumonia;
• cystitis;
• pyelonephritis;
• skin and soft tissue infections, including cellulitis, animal bites, severe dentoalveolar abscesses with widespread cellulitis;
• bone and joint infections, including osteomyelitis.

Film-coated tablets 875 mg/125 mg.

Treatment of bacterial infections in adults and children caused by microorganisms sensitive to the drug, such as:

• acute bacterial sinusitis;
• acute otitis media;
• confirmed exacerbation of chronic bronchitis;
• nosocomial pneumonia;
• cystitis;
• pyelonephritis;
• skin and soft tissue infections, including cellulitis, animal bites, severe dentoalveolar abscesses with widespread cellulitis;
• bone and joint infections, including osteomyelitis.